Symbols / NVCR
NVCR Chart
About
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.59B |
| Enterprise Value | 1.08B | Income | -177.65M | Sales | 642.27M |
| Book/sh | 3.05 | Cash/sh | 9.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1488 | IPO | — |
| P/E | — | Forward P/E | -8.89 | PEG | — |
| P/S | 2.48 | P/B | 4.66 | P/C | — |
| EV/EBITDA | -6.78 | EV/Sales | 1.68 | Quick Ratio | 1.49 |
| Current Ratio | 1.55 | Debt/Eq | 233.77 | LT Debt/Eq | — |
| EPS (ttm) | -1.61 | EPS next Y | -1.60 | EPS Growth | — |
| Revenue Growth | 7.80% | Earnings | 2026-02-26 | ROA | -8.30% |
| ROE | -50.60% | ROIC | — | Gross Margin | 75.53% |
| Oper. Margin | -21.54% | Profit Margin | -27.66% | Shs Outstand | 111.98M |
| Shs Float | 92.51M | Short Float | 11.23% | Short Ratio | 6.84 |
| Short Interest | — | 52W High | 22.30 | 52W Low | 9.82 |
| Beta | 0.73 | Avg Volume | 1.83M | Volume | 1.30M |
| Target Price | $25.21 | Recom | Buy | Prev Close | $11.74 |
| Price | $14.21 | Change | 21.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.21
Mean price target
2. Current target
$14.21
Latest analyst target
3. DCF / Fair value
$4.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.21
Low
$13.50
High
$47.00
Mean
$25.21
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-12 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2026-01-15 | reit | Wedbush | Neutral → Neutral | $18 |
| 2026-01-13 | main | HC Wainwright & Co. | Buy → Buy | $39 |
| 2025-10-30 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-10-27 | main | JP Morgan | Neutral → Neutral | $23 |
| 2025-07-25 | down | Wells Fargo | Overweight → Equal-Weight | $15 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $30 |
| 2025-06-27 | reit | Piper Sandler | Overweight → Overweight | $34 |
| 2025-04-23 | main | Piper Sandler | Overweight → Overweight | $34 |
| 2025-04-16 | main | Wedbush | Neutral → Neutral | $27 |
| 2025-04-10 | main | JP Morgan | Neutral → Neutral | $28 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-13 | main | Piper Sandler | Overweight → Overweight | $42 |
| 2024-12-03 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-02 | up | Evercore ISI Group | In-Line → Outperform | $30 |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-16 | up | HC Wainwright & Co. | Neutral → Buy | $30 |
| 2024-10-01 | main | Evercore ISI Group | In-Line → In-Line | $18 |
- $NVCR stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 25 Feb 2026 14
- BC becomes first province to fund Novocure brain cancer therapy - Stock Titan ue, 24 Feb 2026 12
- What’s Happening With NovoCure Stock? - Forbes hu, 12 Feb 2026 08
- Interesting NVCR Put And Call Options For April 17th - Nasdaq ue, 24 Feb 2026 15
- Novocure stock jumps after Medicare billing restored - Investing.com India Wed, 25 Feb 2026 14
- NovoCure Has Medicare Billing Privileges Reinstated by CMS - TipRanks ue, 24 Feb 2026 23
- Risk Check: Is NVCR stock heavily shorted - 2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn Wed, 25 Feb 2026 10
- NovoCure Limited (NVCR) Investor Outlook: Exploring A Potential 129.64% Upside - DirectorsTalk Interviews Wed, 25 Feb 2026 04
- NovoCure Stock Pre-Market (+30%) : FDA Approval for Pancreatic Cancer Device - Trefis hu, 12 Feb 2026 11
- Novocure shares surge after FDA approves Optune Pax for pancreatic cancer (NVCR:NASDAQ) - Seeking Alpha hu, 12 Feb 2026 08
- Why NVCR Stock Is Surging Nearly 30% In Overnight Trading - Stocktwits Wed, 11 Feb 2026 08
- NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know - Bitget Wed, 11 Feb 2026 08
- $NVCR stock is up 35% today. Here's what we see in our data. - Quiver Quantitative hu, 12 Feb 2026 08
- Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know - Nasdaq hu, 19 Feb 2026 15
- NovoCure Limited (NVCR) Stock Analysis: Unveiling a 129% Upside Potential in the Tumor Treating Fields Market - DirectorsTalk Interviews ue, 17 Feb 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 108 | 1187 | — | Stock Award(Grant) at price 10.99 per share. | BEN ARYE BARAK | General Counsel | — | 2025-12-31 00:00:00 | D |
| 1 | 1 | 11 | — | Stock Award(Grant) at price 10.99 per share. | PURI MICHAL NATH | Officer | — | 2025-12-31 00:00:00 | D |
| 2 | 1 | 11 | — | Stock Award(Grant) at price 10.99 per share. | DANZIGER ASAF | Director | — | 2025-12-31 00:00:00 | D |
| 3 | 81550 | 996859 | — | Purchase at price 12.22 per share. | CORDOVA ASHLEY | Chief Executive Officer | — | 2025-09-05 00:00:00 | D |
| 4 | 20000 | 231800 | — | Purchase at price 11.50 - 11.63 per share. | BRACKMANN CHRISTOPH | Chief Financial Officer | — | 2025-07-29 00:00:00 | D |
| 5 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | LEONARD FRANCIS XAVIER II | Officer | — | 2025-06-30 00:00:00 | D |
| 6 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | CORDOVA ASHLEY | Chief Executive Officer | — | 2025-06-30 00:00:00 | D |
| 7 | 769 | 11635 | — | Stock Award(Grant) at price 15.13 per share. | BEN ARYE BARAK | General Counsel | — | 2025-06-30 00:00:00 | D |
| 8 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | PURI MICHAL NATH | Officer | — | 2025-06-30 00:00:00 | D |
| 9 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | DANZIGER ASAF | Director | — | 2025-06-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -150.57K | -167.37K | -739.83K | -1.09M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -108.87M | -176.66M | -64.36M | -34.35M |
| TotalUnusualItems | -717.00K | -797.00K | -3.52M | -4.03M |
| TotalUnusualItemsExcludingGoodwill | -717.00K | -797.00K | -3.52M | -4.03M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -168.63M | -207.04M | -92.53M | -58.35M |
| ReconciledDepreciation | 11.23M | 10.97M | 10.62M | 10.25M |
| ReconciledCostOfRevenue | 137.18M | 128.28M | 114.87M | 114.88M |
| EBITDA | -109.58M | -177.45M | -67.89M | -38.38M |
| EBIT | -120.82M | -188.42M | -78.51M | -48.63M |
| NetInterestIncome | 40.05M | 41.93M | 11.20M | -3.71M |
| InterestExpense | 10.34M | 3.32M | 3.33M | 3.44M |
| InterestIncome | 22.72M | 19.64M | 10.96M | 791.00K |
| NormalizedIncome | -168.06M | -206.41M | -89.75M | -55.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -168.63M | -207.04M | -92.53M | -58.35M |
| TotalExpenses | 775.72M | 742.21M | 627.36M | 579.36M |
| TotalOperatingIncomeAsReported | -170.50M | -232.87M | -89.52M | -44.33M |
| DilutedAverageShares | 107.83M | 106.39M | 104.66M | 103.43M |
| BasicAverageShares | 107.83M | 106.39M | 104.66M | 103.43M |
| DilutedEPS | -1.56 | -1.95 | -0.88 | -0.56 |
| BasicEPS | -1.56 | -1.95 | -0.88 | -0.56 |
| DilutedNIAvailtoComStockholders | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeCommonStockholders | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncome | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeIncludingNoncontrollingInterests | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeContinuousOperations | -168.63M | -207.04M | -92.53M | -58.35M |
| TaxProvision | 37.47M | 15.30M | 10.69M | 6.28M |
| PretaxIncome | -131.16M | -191.74M | -81.85M | -52.08M |
| OtherIncomeExpense | -717.00K | -797.00K | -3.52M | -4.03M |
| GainOnSaleOfSecurity | -717.00K | -797.00K | -3.52M | -4.03M |
| NetNonOperatingInterestIncomeExpense | 40.05M | 41.93M | 11.20M | -3.71M |
| TotalOtherFinanceCost | -27.67M | -25.61M | -3.57M | 1.06M |
| InterestExpenseNonOperating | 10.34M | 3.32M | 3.33M | 3.44M |
| InterestIncomeNonOperating | 22.72M | 19.64M | 10.96M | 791.00K |
| OperatingIncome | -170.50M | -232.87M | -89.52M | -44.33M |
| OperatingExpense | 638.53M | 613.93M | 512.50M | 464.49M |
| ResearchAndDevelopment | 209.65M | 223.06M | 206.09M | 201.30M |
| SellingGeneralAndAdministration | 428.89M | 390.87M | 306.41M | 263.18M |
| SellingAndMarketingExpense | 239.06M | 226.81M | 173.66M | 137.06M |
| GeneralAndAdministrativeExpense | 189.83M | 164.06M | 132.75M | 126.13M |
| OtherGandA | 189.83M | 164.06M | 132.75M | 126.13M |
| GrossProfit | 468.04M | 381.06M | 422.97M | 420.15M |
| CostOfRevenue | 137.18M | 128.28M | 114.87M | 114.88M |
| TotalRevenue | 605.22M | 509.34M | 537.84M | 535.03M |
| OperatingRevenue | 605.22M | 509.34M | 537.84M | 535.03M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 108.52M | 107.08M | 105.05M | 103.97M |
| ShareIssued | 108.52M | 107.08M | 105.05M | 103.97M |
| NetDebt | 491.69M | 328.00M | 450.18M | 353.41M |
| TotalDebt | 683.35M | 604.56M | 584.27M | 575.21M |
| TangibleBookValue | 360.18M | 362.50M | 441.17M | 410.49M |
| InvestedCapital | 1.02B | 931.32M | 1.01B | 972.71M |
| WorkingCapital | 350.20M | 855.29M | 952.75M | 930.92M |
| NetTangibleAssets | 360.18M | 362.50M | 441.17M | 410.49M |
| CapitalLeaseObligations | 27.89M | 35.74M | 18.76M | 13.00M |
| CommonStockEquity | 360.18M | 362.50M | 441.17M | 410.49M |
| TotalCapitalization | 457.48M | 931.32M | 1.01B | 972.71M |
| TotalEquityGrossMinorityInterest | 360.18M | 362.50M | 441.17M | 410.49M |
| StockholdersEquity | 360.18M | 362.50M | 441.17M | 410.49M |
| GainsLossesNotAffectingRetainedEarnings | -5.50M | -5.47M | -2.43M | -3.17M |
| OtherEquityAdjustments | -5.50M | -5.47M | -2.43M | -3.17M |
| RetainedEarnings | -1.15B | -985.50M | -778.46M | -685.93M |
| AdditionalPaidInCapital | 1.52B | 1.35B | 1.22B | 1.10B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 880.61M | 783.63M | 750.48M | 729.00M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 124.23M | 604.52M | 591.70M | 586.40M |
| OtherNonCurrentLiabilities | 18.00K | 18.00K | 148.00K | 166.00K |
| EmployeeBenefits | 6.94M | 8.26M | 4.40M | 4.54M |
| NonCurrentDeferredLiabilities | 0.00 | 2.88M | 6.48M | |
| NonCurrentDeferredRevenue | 0.00 | 2.88M | 6.48M | |
| LongTermDebtAndCapitalLeaseObligation | 117.27M | 596.24M | 584.27M | 575.21M |
| LongTermCapitalLeaseObligation | 19.97M | 27.42M | 18.76M | 13.00M |
| LongTermDebt | 97.30M | 568.82M | 565.51M | 562.22M |
| CurrentLiabilities | 756.38M | 179.12M | 158.78M | 142.60M |
| CurrentDeferredLiabilities | 14.22M | 16.22M | 18.03M | 17.76M |
| CurrentDeferredRevenue | 14.22M | 16.22M | 18.03M | 17.76M |
| CurrentDebtAndCapitalLeaseObligation | 566.08M | 8.32M | ||
| CurrentCapitalLeaseObligation | 7.92M | 8.32M | ||
| CurrentDebt | 558.16M | |||
| OtherCurrentBorrowings | 558.16M | |||
| PayablesAndAccruedExpenses | 176.07M | 154.57M | 140.75M | 124.84M |
| CurrentAccruedExpenses | 70.98M | 60.18M | 55.55M | 52.24M |
| Payables | 105.09M | 94.39M | 85.20M | 72.60M |
| AccountsPayable | 105.09M | 94.39M | 85.20M | 72.60M |
| TotalAssets | 1.24B | 1.15B | 1.19B | 1.14B |
| TotalNonCurrentAssets | 134.21M | 111.72M | 80.12M | 65.97M |
| OtherNonCurrentAssets | 14.62M | 14.02M | 11.16M | 12.09M |
| NetPPE | 119.59M | 97.70M | 68.96M | 53.88M |
| AccumulatedDepreciation | -58.41M | -54.81M | -47.64M | -42.96M |
| GrossPPE | 178.00M | 152.51M | 116.60M | 96.84M |
| Leases | 12.13M | 11.70M | 9.35M | 7.08M |
| OtherProperties | 84.49M | 80.71M | 63.84M | 54.43M |
| MachineryFurnitureEquipment | 46.85M | 35.41M | 27.43M | 24.18M |
| LandAndImprovements | 34.53M | 24.70M | 15.99M | 11.15M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.11B | 1.03B | 1.11B | 1.07B |
| RestrictedCash | 2.33M | 1.74M | 508.00K | 807.00K |
| PrepaidAssets | 7.22M | 6.78M | 6.20M | 4.71M |
| Inventory | 35.09M | 38.15M | 29.38M | 24.43M |
| FinishedGoods | 23.11M | 18.09M | 15.74M | 14.67M |
| WorkInProcess | 7.97M | 9.80M | 9.32M | 8.27M |
| RawMaterials | 4.00M | 10.27M | 4.31M | 1.49M |
| Receivables | 102.07M | 77.11M | 106.03M | 105.88M |
| OtherReceivables | 27.85M | 15.89M | 19.76M | 12.31M |
| AccountsReceivable | 74.23M | 61.22M | 86.26M | 93.57M |
| CashCashEquivalentsAndShortTermInvestments | 959.87M | 910.62M | 969.42M | 937.70M |
| OtherShortTermInvestments | 796.11M | 669.79M | 854.10M | 728.90M |
| CashAndCashEquivalents | 163.77M | 240.82M | 115.33M | 208.80M |
| CashEquivalents | 151.92M | 230.87M | 105.63M | 205.66M |
| CashFinancial | 11.85M | 9.96M | 9.70M | 3.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -69.22M | -100.43M | 9.43M | 58.59M |
| RepaymentOfDebt | -12.91M | -10.00K | -28.00K | -26.00K |
| IssuanceOfDebt | 96.92M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 4.15M | 4.42M | 5.22M | 4.55M |
| CapitalExpenditure | -42.85M | -27.09M | -21.36M | -24.17M |
| InterestPaidSupplementalData | 7.71M | 6.00K | 41.00K | 101.00K |
| IncomeTaxPaidSupplementalData | 23.46M | 13.66M | 5.48M | 3.11M |
| EndCashPosition | 166.09M | 242.56M | 115.83M | 209.61M |
| BeginningCashPosition | 242.56M | 115.83M | 209.61M | 246.17M |
| EffectOfExchangeRateChanges | -174.00K | 131.00K | -97.00K | -188.00K |
| ChangesInCash | -76.30M | 126.60M | -93.68M | -36.38M |
| FinancingCashFlow | 90.31M | 15.79M | 15.49M | 25.70M |
| CashFlowFromContinuingFinancingActivities | 90.31M | 15.79M | 15.49M | 25.70M |
| ProceedsFromStockOptionExercised | 2.16M | 11.38M | 10.29M | 21.18M |
| NetCommonStockIssuance | 4.15M | 4.42M | 5.22M | 4.55M |
| CommonStockIssuance | 4.15M | 4.42M | 5.22M | 4.55M |
| NetIssuancePaymentsOfDebt | 84.01M | -10.00K | -28.00K | -26.00K |
| NetLongTermDebtIssuance | 84.01M | -10.00K | -28.00K | -26.00K |
| LongTermDebtPayments | -12.91M | -10.00K | -28.00K | -26.00K |
| LongTermDebtIssuance | 96.92M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -140.24M | 184.15M | -139.96M | -144.83M |
| CashFlowFromContinuingInvestingActivities | -140.24M | 184.15M | -139.96M | -144.83M |
| NetInvestmentPurchaseAndSale | -97.39M | 211.24M | -118.60M | -120.66M |
| SaleOfInvestment | 778.00M | 1.21B | 1.18B | 958.00M |
| PurchaseOfInvestment | -875.39M | -1.00B | -1.30B | -1.08B |
| NetPPEPurchaseAndSale | -42.85M | -27.09M | -21.36M | -24.17M |
| PurchaseOfPPE | -42.85M | -27.09M | -21.36M | -24.17M |
| OperatingCashFlow | -26.37M | -73.34M | 30.79M | 82.76M |
| CashFlowFromContinuingOperatingActivities | -26.37M | -73.34M | 30.79M | 82.76M |
| ChangeInWorkingCapital | -3.65M | 29.66M | 11.80M | 29.07M |
| ChangeInOtherCurrentLiabilities | -6.36M | -9.78M | -7.77M | -10.98M |
| ChangeInOtherCurrentAssets | 7.39M | 4.07M | 7.11M | 4.52M |
| ChangeInPayablesAndAccruedExpense | 19.11M | 14.87M | 14.26M | 27.78M |
| ChangeInInventory | 2.57M | -8.92M | -4.34M | 2.48M |
| ChangeInReceivables | -26.36M | 29.41M | 2.55M | 5.27M |
| ChangesInAccountReceivables | -26.36M | 29.41M | 2.55M | 5.27M |
| OtherNonCashItems | -651.00K | -95.00K | -2.22M | -94.00K |
| StockBasedCompensation | 160.03M | 115.61M | 106.95M | 94.90M |
| AssetImpairmentCharge | 1.16M | 493.00K | 955.00K | 649.00K |
| AmortizationOfSecurities | -25.64M | -23.08M | -1.54M | 3.10M |
| DepreciationAmortizationDepletion | 11.23M | 10.97M | 10.62M | 10.25M |
| DepreciationAndAmortization | 11.23M | 10.97M | 10.62M | 10.25M |
| OperatingGainsLosses | -227.00K | 161.00K | -3.26M | 3.23M |
| NetForeignCurrencyExchangeGainLoss | -227.00K | 161.00K | -3.26M | 3.23M |
| NetIncomeFromContinuingOperations | -168.63M | -207.04M | -92.53M | -58.35M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NVCR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|